Last reviewed · How we verify
NCT04687332
IA or PE - What is the Best Treatment Option of Steroid Refractory Neurological Autoimmune Diseases
NA trial testing Apheresis therapy by Octo Nova Technology (DIAMED, Cologne, Germany) in Neurological Autoimmune Diseases in 32 participants. Completed in 1 December 2019.
15 September 2019
Quick facts
| Lead sponsor | University Medical Center Mainz |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 1 June 2016 |
| Primary completion | 15 September 2019 |
| Estimated completion | 1 December 2019 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Apheresis therapy by Octo Nova Technology (DIAMED, Cologne, Germany)
Conditions studied
- Neurological Autoimmune Diseases — all drugs for Neurological Autoimmune Diseases →
Sponsor
University Medical Center Mainz
Who can join
Adults 18 to 80, any sex, with Neurological Autoimmune Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this prospective controlled monocentric observational study, we assessed safety and efficacy of therapy with IA or PE in patients with neurological autoimmune diseases. In the subgroup analysis of MS patients also the EDSS was evaluated. In addition, we investigated possible pathomechanisms, such as cytokine alterations under therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04687332
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neurological Autoimmune Diseases
Currently open trials in the same condition.
- NCT07275736 — A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases · EARLY_PHASE1 · recruiting
- NCT07021209 — GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases · Phase 1 · recruiting
- NCT07197099 — Evaluation for Therapeutic Plasma Exchange for Immune Mediated Neurological Disease · recruiting
Other University Medical Center Mainz trials
Trials by the same sponsor.
- NCT05877768 — Evaluation of PCD-CT Based Image Parameters in the Assessment and Quantification of Coronary Artery Disease · not yet recruiting
- NCT06129617 — Intermittent ADVOS vs. Hemodialysis in Non-intensive Care Patients With Liver Dysfunction · NA · recruiting
- NCT05841498 — Immunoadsorption Study Mainz in Adults With Post-COVID Syndrome · NA · completed
- NCT04306458 — RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial). · NA · recruiting
- NCT03942718 — Systemic Lupus Erythematosus Exercise Program · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04687332 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Medical Center Mainz
- Last refreshed: 17 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04687332.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing